Registered outcomes23

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 20 of 23

List	Outcome	Time frame	Description
Primary	Incidence of Treatment Emergent Adverse Events [Safety and Tolerability]	Through Day 60	Adverse Events experienced by the patients from randomization to Day 60 (including vital signs, physical findings, clinical laboratory, and ECG results) as characterized by type, frequency, severity (as graded by Common Terminology Criteria for Adverse Events (CTCAE version 5.0), timing, seriousness, and relationship to study therapy.
Secondary	To Compare Time to Clinical Recovery in CX-4945 Treatment Group Evaluated From Randomization Through Day 28 as Compared to the Control Arm.	Through Day 28	Number of days from randomization to discharge, or to alleviation of cough (defined as mild or absent in a patient reported scale of 0=absent, 1=mild, 2=moderate, and 3=severe). Improvement must be sustained for at least 48 hours.
Secondary	To Compare Time to Clinical Recovery in CX-4945 Treatment Group Evaluated From Randomization Through Day 28 as Compared to the Control Arm.	Through hospital discharge, an average of 28 days	Number of days from randomization to normalization of fever (defined as \<36.6°C from axillary site, or \< 37.2°C from oral site or \< 37.8°C from rectal or tympanic site), normalization of respiratory rate (\< 24 bpm while breathing room air), resolution of hypoxia (defined as SpO2 ≥ 93% in room air or P/F ≥ 300 mmHg). All these improvements must be sustained for at least 48 hours.
Secondary	To Compare Time to Clinical Recovery in CX-4945 Treatment Group Evaluated From Randomization Through Day 28 as Compared to the Control Arm.	Through Day 28	Number of days from randomization to the first day on which the subject satisfies one of the following three categories from the ordinal NIAID 8- point Clinical Progression Outcomes scale collected daily from randomization through Day 28: Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; Not hospitalized, limitation on activities and/or requiring home oxygen; Not hospitalized, no limitations on activities.
Secondary	To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28.	Assessed on Day 14 and Day 28	Difference in percentage of subjects with clinical recovery compared at Day 14 and Day 28.
Secondary	To Compare Changes in Clinical Status of Patients Enrolled to CX-4945 Treatment Arm as Compared to the Control Arm at Day 14 and Day 28.	Through Day 28	Percentage of Participants at Each Clinical Status at Day 14 and Day 28 assessed by using the ordinal NIAID 8- point Clinical Progression Outcomes scale (Scale ranges from 1 (Death) to 8 (Not hospitalized, no limitations on activities)
Secondary	To Evaluate Preliminary Evidence of Anti-viral Activity of CX-4945 as Compared to the Control Arm.	Assessed at Day 1, Day 8, Day 14 and Day 28	Difference in proportions of patients with conversion of positive RT-PCR to negative RT-PCR as assessed at Day 1, Day 8, Day 14 and Day 28.
Secondary	To Evaluate Preliminary Evidence of Anti-viral Activity of CX-4945 as Compared to the Control Arm.	Through Day 14	Changes in chest imaging from Screening to Day 5 or 14
Secondary	Number of Days Hospitalized	Through Day 28	Days of hospitalization from randomization through Day 28
Secondary	To Evaluate Changes in IL-6 Level	Assessed on Days 1, 4, 8, 11, and 14	IL-6 level
Secondary	To Evaluate Changes in CRP	Assessed on Days 1, 4, 8, 11, and 14	CRP level
Secondary	To Evaluate Changes in LDH	Assessed on Days 1, 4, 8, 11, and 14	LDH level
Secondary	To Evaluate Changes in CPK	Assessed on Days 1, 4, 8, 11, and 14	CPK level
Secondary	To Evaluate Changes in Ferritin	Assessed on Days 1, 4, 8, 11, and 14	Ferritin level
Secondary	To Evaluate Changes in D-dimer	Assessed on Days 1, 4, 8, 11, and 14	D-dimer level
Secondary	Number of Days of Supplemental Oxygen Use	Through Day 28	Days of supplemental oxygen (if applicable) from randomization through day 28
Secondary	All-cause Mortality Status	Through Day 60	The number of deaths occurred in each treatment group from randomization through Day 60
Secondary	Number of Days of On-invasive Ventilation/High Flow Oxygen	Through Day 28	Days of non-invasive ventilation/high flow oxygen (if applicable) from randomization through day 28
Secondary	Number of Days of Invasive Mechanical Ventilation/ECMO	Through Day 28	Days of invasive mechanical ventilation/ECMO (if applicable) from randomization through Day 28.
Secondary	Number of Patients Returned to Room Air	Through Day 28	Number of patients returned to room air after randomization through Day 14 or Day 28.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04668209/registered

API reference For AI assistants

Registered outcomes23

Sources 3

Read this list from software.